Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | BCL9 | O00512 | 1/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400861 | 0.88 | HTR2A (0.61) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL4112112 | 0.88 | HTR2A (0.74) | HTR2ABCL9CTNNB1GAAPOLB | |
| SCHEMBL1311504 | 0.87 | HTR2A (0.62) | HTR2ABCL9CTNNB1GAAPOLB | |
| Water SCHEMBL10938430 | 0.86 | HTR2A (0.73) | HTR2ABCL9CTNNB1GAAPOLB | |
| Water SCHEMBL10938437 | 0.86 | HTR2A (0.73) | HTR2ABCL9CTNNB1GAAPOLB | |
| SCHEMBL5827968 | 0.86 | HTR2A (0.80) | HTR2ABCL9CTNNB1GAAHTT | |
| SCHEMBL7164084 | 0.85 | HTR2A (0.64) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL17084531 | 0.85 | HTR2A (0.63) | HTR2ABCL9CTNNB1GAAPOLB | |
| SCHEMBL30679539 | 0.84 | HTR2A (0.62) | HTR2ABCL9CTNNB1GAAMAPT | |
| SCHEMBL31413357 | 0.84 | HTR2A (0.62) | HTR2ABCL9CTNNB1GAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100357267-C | Use of 2, 4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | NOVARTIS AG (CH) | 2007-12-26 | — | — | CN | disclosed |
| US-20050026994-A1 | Use of 2, 4diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | FRANCE DENNIS (US) | 2005-02-03 | — | — | US | disclosed |
| EP-1173413-B1 | USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES AS PROTEASOME INHIBITORS | NOVARTIS AG (CH) | 2004-06-30 | — | — | EP | disclosed |
| CN-1351587-A | Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | NOVARTIS AG (CH) | 2002-05-29 | — | — | CN | disclosed |
| EP-1173413-A1 | USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES AS PROTEASOME INHIBITORS | Novartis AG (CH) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000064863-A1 | USE OF 2,4-DIAMINO-3-HYDROXYCARBOXYLIC ACID DERIVATIVES AS PROTEASOME INHIBITORS | NOVARTIS AG (CH) | 2000-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026994-A1 | Use of 2, 4diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors | PSMB3, PSMB2, PSMB1 | HTR2A 972/4885BCL9 123/4885CTNNB1 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.